Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Upjohn

Executive Summary

Generic versions of nonsteroidal anti-inflammatory drug Ansaid (flurbiprofen), oral anti-diabetic agent Micronase (glyburide) and acne treatment Cleocin-T Topical Solution (clindamycin) will be marketed "at a later date" by Ciba-Geigy generics subsidiary Geneva under an expanded agreement announced March 29. On Jan. 1, Upjohn formed Greenstone, Ltd. to supply Geneva with generic versions of the benzodiazepines Halcion (triazolam) and Xanax (alprazolam). Upjohn's patent for Ansaid expired Feb. 19. Micronase loses exclusivity May 1, 1994 and Cleocin-T is patented until July 13, 1993.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel